Table 1.

F→M HCT patient characteristics

Characteristicn
Total subjects28
Primary disease
 Acute myelogenous leukemia10
 Non-Hodgkin lymphoma4
 Acute lymphoblastic leukemia3
 Chronic lymphocytic leukemia3
 Chronic myelogenous leukemia3
 Other5
Age, median (range), y54 (21–65)
Conditioning regimen
 Myeloablative13 (46%)
 Nonmyeloablative15 (54%)
Donor
 Related16 (57%)
 Unrelated12 (43%)
cGVHD
 None8 (29%)
 Mild3 (11%)
 Moderate12 (43%)
 Severe5 (17%)
aGVHD
 Grade II–IV9 (32%)
 None–grade I19 (68%)
Survival, median (range), y3.2 y (1–5.9)